國立虎尾科技大學 |

Current Immunotherapeutic Strategies in Cancer

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Current Immunotherapeutic Strategies in Cancer/ edited by Matthias Theobald.
other author:	Theobald, Matthias.
Description:	V, 187 p.online resource. :
Contained By:	Springer Nature eBook
Subject:	Oncology . -
Online resource:	https://doi.org/10.1007/978-3-030-23765-3
ISBN:	9783030237653

Current Immunotherapeutic Strategies in Cancer
Current Immunotherapeutic Strategies in Cancer[electronic resource] /edited by Matthias Theobald. - 1st ed. 2020. - V, 187 p.online resource. - Recent Results in Cancer Research,2140080-0015 ;. - Recent Results in Cancer Research,200.

Current Development of Monoclonal Antibodies in Cancer Therapy -- Clinical Experience with Bispecific T-Cell Engagers -- Advances and challenges of CAR-modified T cells in clinical trials -- Targeting Cancer with Genetically Engineered TCR-T Cells -- Tailored Vaccines Based on Patient’s Cancer Mutanome -- Next-Generation Checkpoint Inhibitors and Immune Agonists.

This book offers a comprehensive review of recent advances in cancer immunotherapy, and explores the value and limitations of the most effective current therapeutic strategies and emerging treatment modalities. It discusses in detail the successes achieved using monoclonal antibodies (mAbs), including developments with regard to conjugated mAbs and also bispecific mAbs as novel treatment options for leukemia and solid tumors. It also examines the advances toward personalized immunotherapy, focusing on the effectiveness of adoptive cell therapy using genetically engineered T cells with tumor-associated antigen-specific T-cell receptors and chimeric antigen receptors, as well as the role of tailored vaccines based on the patient’s cancer mutanome. Further, it describes the impressive therapeutic results recently achieved with checkpoint inhibitors, and analyzes novel strategies to modulate the immunosuppressive tumor microenvironment. Written by leading international experts and providing up-to-date information on emerging strategies, such as oncolytic virus-based therapy, epigenetic therapy, and combination therapy, the book appeals to all those with an interest in immunotherapy as it comes of age.

ISBN: 9783030237653

Standard No.: 10.1007/978-3-030-23765-3doiSubjects--Topical Terms:

1253469
Oncology .

LC Class. No.: RC254-282

Dewey Class. No.: 616.994

Current Immunotherapeutic Strategies in Cancer
LDR:02952nam a22004095i 4500 001 1023083
003 DE-He213
005 20200706034349.0
007 cr nn 008mamaa
008 210318s2020 gw | s |||| 0|eng d
020 $a 9783030237653 $9 978-3-030-23765-3
024 7 $a 10.1007/978-3-030-23765-3 $2 doi
035 $a 978-3-030-23765-3
050 4 $a RC254-282
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 616.994 $2 23
245 1 0 $a Current Immunotherapeutic Strategies in Cancer $h [electronic resource] / $c edited by Matthias Theobald.
250 $a 1st ed. 2020.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2020.
300 $a V, 187 p. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Recent Results in Cancer Research, $x 0080-0015 ; $v 214
505 0 $a Current Development of Monoclonal Antibodies in Cancer Therapy -- Clinical Experience with Bispecific T-Cell Engagers -- Advances and challenges of CAR-modified T cells in clinical trials -- Targeting Cancer with Genetically Engineered TCR-T Cells -- Tailored Vaccines Based on Patient’s Cancer Mutanome -- Next-Generation Checkpoint Inhibitors and Immune Agonists.
520 $a This book offers a comprehensive review of recent advances in cancer immunotherapy, and explores the value and limitations of the most effective current therapeutic strategies and emerging treatment modalities. It discusses in detail the successes achieved using monoclonal antibodies (mAbs), including developments with regard to conjugated mAbs and also bispecific mAbs as novel treatment options for leukemia and solid tumors. It also examines the advances toward personalized immunotherapy, focusing on the effectiveness of adoptive cell therapy using genetically engineered T cells with tumor-associated antigen-specific T-cell receptors and chimeric antigen receptors, as well as the role of tailored vaccines based on the patient’s cancer mutanome. Further, it describes the impressive therapeutic results recently achieved with checkpoint inhibitors, and analyzes novel strategies to modulate the immunosuppressive tumor microenvironment. Written by leading international experts and providing up-to-date information on emerging strategies, such as oncolytic virus-based therapy, epigenetic therapy, and combination therapy, the book appeals to all those with an interest in immunotherapy as it comes of age.
650 0 $a Oncology . $3 1253469
650 0 $a Immunology. $3 592892
650 1 4 $a Oncology. $3 593951
700 1 $a Theobald, Matthias. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1318940
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783030237646
776 0 8 $i Printed edition: $z 9783030237660
776 0 8 $i Printed edition: $z 9783030237677
830 0 $a Recent Results in Cancer Research, $x 0080-0015 ; $v 200 $3 1263334
856 4 0 $u https://doi.org/10.1007/978-3-030-23765-3
912 $a ZDB-2-SME
912 $a ZDB-2-SXM
950 $a Medicine (SpringerNature-11650)
950 $a Medicine (R0) (SpringerNature-43714)